Press Releases
Portland, Oregon--(Newsfile Corp. - June 1, 2024) - Aisles has recently unveiled its innovative AI system, WATCH, designed to revolutionize monitoring and managing public safety across varied environments such as highways, city centers, and other high-traffic areas. With its advanced capabilities, WATCH is set to significantly improve the efficiency of emergency response and enhance public safety management.
Watch
To view an enhanced version of this graphic, please visit:... (continue reading...)
CIO Women Magazine Spotlights Claudia Patricia Eusse, CEO of The Eusse Group, as a top real estate leader: Celebrating her journey from broadcast journalism to real estate, driving over $200 million in sales, and advocating for gender equality.
Columbus, Ohio Jun 1, 2024 (Issuewire.com) - CIO Women Magazine, a premier digital business publication focusing on women business leaders, is proud to feature Claudia Patricia Eusse, CEO of The Eusse Group, in its latest issue: "... (continue reading...)
Mr. Business Magazine spotlights Diana Muniz-Lebrun, CEO of Olympus Marketing, as an inspiring female leader. With over 20 years in marketing, her visionary leadership and global experience drive Olympus to digital innovation and success.
San Jose, California Jun 1, 2024 (Issuewire.com) - Mr. Business Magazine, a leading digital publication focusing on the intricacies of the business world, proudly presents its latest issue: "Most Inspiring Female Leaders Making a... (continue reading...)
BREA, Calif., June 1, 2024 /PRNewswire/ -- ICECO, a leading expert in portable refrigeration solutions, announces the launch of the world's lightest dual-zone aluminum portable freezer, the APL35, on Indiegogo on June 1st at 8 AM PDT: https://igg.me/at/icecoapl35. The APL35 redefines portable refrigeration with its ultra-aesthetic design, ultra-light build, and ultra-energy efficiency, making it an essential companion for outdoor enthusiasts.
- An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy
- SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg
- No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)
- Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all... (continue reading...)
More Press Releases
View Older Stories-
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Gregory P Lee Personal Injury Lawyer The Woodlands Expands Services to Meet Rising Demand in Texas for Personal Injury Cases
-
Innovative Solutions and Cutting-Edge Technologies Take Centre Stage at Water Expo Delhi 2024
-
Revolutionizing Sustainability: The Environment Protection Technologies Expo
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
Fungies Mushroom Gummies Announces Major Retail Expansion and Availability at Walmart
-
Vincent Todd Announces the Introduction of Todd Agriscience
-
Hyundai Motor America Reports May 2024 Sales
-
Beverly Hills MD Celebrates Its 10th Anniversary
-
American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
5 Ways BPO Services Can Improve Your Business Operations
-
Amazed by these incredible facts about the yellow diamond
-
Maximizing Efficiency: The Role of Content Moderation Services
-
Wisconsin Top Performing Stocks
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
-
James Avery Artisan Jewelry Opens New Store at Westover Marketplace
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
-
BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
-
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
-
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit